Targeting TPX2-dependent lineage plasticity by CDK4/6 inhibition reverses therapy resistance in neuroendocrine bladder carcinoma - PubMed
5 hours ago
- #CDK4/6 inhibitors
- #TPX2
- #neuroendocrine bladder carcinoma
- TPX2-high cells in neuroendocrine bladder carcinoma (NEBC) show increased lineage plasticity and are linked to poor clinical outcomes.
- These TPX2-high cells lack typical neuroendocrine markers, disrupt cell cycle progression, and create an immunosuppressive niche that leads to CD8+ T cell exhaustion.
- Targeting TPX2-dependent lineage plasticity with CDK4/6 inhibitors, combined with immune checkpoint blockade, effectively reverses therapy resistance in preclinical models.